Robbins LLP is Investigating Allegations that Beta Bionics, Inc. (BBNX) Misled Investors Regarding the Efficacy of its iLet Bionic Pancreas Insulin Pump

Robbins LLP informs investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Beta Bionics, Inc. (NASDAQ: BBNX) common stock between July 30, 2025 and February 24, 2026, inclusive (the "Class Period"). Beta Bionics is a commercial-stage medical device company that offers an automated insulin delivery system for the treatment of diabetes, known as the iLet Bionic Pancreas insulin pump (“iLet”).

Why Was Beta Bionics Sued?

The complaint alleges that during the Class Period defendants touted the safety, efficacy, and commercial success of iLet—the Company’s sole commercialized device. In October 2025, Beta Bionics disclosed that it had received an FDA Form 483 raising concerns about iLet. Defendants stressed that the letter had nothing to do with the safety or efficacy of the device itself. Rather, defendants stated that the FDA had only taken issue with the Company’s interpretation of which customer complaints needed to be reported to the FDA, such that the Company would have to backfile some additional customer complaints that were very minor in nature and required no medical intervention. Further, defendants assured investors that the Company was swiftly implementing the FDA’s required changes to its complaint reporting system, and accordingly that they did not “foresee any ongoing challenge with this at all.”

Plaintiff alleges that defendants’ statements were materially false and misleading. The FDA had in fact raised numerous serious issues with the iLet device itself, namely that the device was malfunctioning and dosing patients with dangerously high levels of insulin, causing hypoglycemic events. Thus, the complaints numbered in the thousands and included hundreds of life-threatening events requiring significant medical intervention. Additionally, the Company had utterly failed to implement any meaningful corrective actions.

Why Did BBNX Stock Drop?

A series of disclosures beginning on January 8, 2026, and concluding on February 24, 2026, revealed that the issues raised in the warning letter went far beyond mere complaint handling.

On February 24, 2026, the full truth was revealed when the FDA publicly released its warning letter detailing a litany of violations and defendants’ failure to correct them, and contradicting months of defendants’ public statements that all back-filed complaints were for entirely benign issues. The warning letter made clear that defendants’ prior interpretation of FDA reporting requirements had not been reasonable and had excluded numerous serious patient incidents that clearly should have been reported.

The stock, which was trading at $31.99 per share on January 9, 2026, fell to $12.89 per share by February 25, 2026.

Who May Be Eligible to Participate in the Beta Bionics Class Action?

The lawsuit seeks to represent investors who purchased or otherwise acquired Beta Bionics, Inc. common stock between July 30, 2025 and February 24, 2026.  Investors who suffered losses during that period may have legal rights under the federal securities laws. Submit a form for information.

Attorney Advertising. Past results do not guarantee a similar outcome.